Press Releases Ionis Pharmaceuticals, Inc.

Equities

IONS

US4622221004

Market Closed - Nasdaq Other stock markets 01:30:00 08/05/2024 am IST			5-day change	1st Jan Change
40.93 ^USD	-3.19%		-0.80%	-19.09%

07/05	Ionis Pharmaceuticals Insider Sold Shares Worth $256,277, According to a Recent SEC Filing	MT
07/05	Transcript : Ionis Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ionis Pharmaceuticals : 1Q24 Earnings Slides	07/05	PU
Ionis Pharmaceuticals: Q1 Earnings Snapshot	07/05	AQ
Ionis reports first quarter 2024 financial results	07/05	PR
Ionis Publishes 2023 Corporate Responsibility Report	25/04	PR
Ionis to hold first quarter 2024 financial results webcast	23/04	PR
Ionis Pharmaceuticals : Listen to webcast	09/04	PU
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome	08/04	AQ
Ionis to present at upcoming investor conferences	01/04	PR
Ionis Pharmaceuticals - Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology annual meeting	26/03	AQ
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH	13/03	PR
Ionis announces new chief global product strategy officer to lead next phase of commercial growth	29/02	PR
Ionis to present at upcoming investor conferences	28/02	PR
Ionis Pharmaceuticals: Q4 Earnings Snapshot	21/02	AQ
Ionis reports fourth quarter and full year 2023 financial results	21/02	PR
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome	15/02	PR
Ionis Pharmaceuticals - Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy	09/02	AQ
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy	08/02	PR
Ionis to hold fourth quarter and full year 2023 financial results webcast	07/02	PR
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema	22/01	PR
Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases	08/01	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Ionis Pharmaceuticals, Inc.

Equities

IONS

US4622221004

Press Releases

Filters